7PO.F Poxel S.A

Healthcare Biotechnology Frankfurt Exchange
0.1484 EUR
Close of Nov 12, 2026
0.1238 0.3830
Market cap
EUR 9.94M
P/E
-
P/B
5.29x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2023.

Is 7PO.F undervalued?

Graham number

The Graham number of Poxel S.A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Poxel S.A fundamental analysis

No fundamental analysis for Poxel S.A yet.

Poxel S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Poxel S.A

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monop…

Full company profile